Department of Medicine, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
J Cardiovasc Pharmacol. 2009 Nov;54(5):451-5. doi: 10.1097/FJC.0b013e3181be7578.
To investigate whether upregulation of OX40-OX40 ligand (OX40L) system is related to stability of coronary atherosclerotic plaque in patients with coronary heart diseases.
Thirty normal controls and 250 patients, including 80 with stable angina (SA), 110 with unstable angina (UA), and 60 with acute myocardial infarction (AMI), were enrolled in our study. The expression of OX40 and OX40L in peripheral CD4 T lymphocytes were analyzed by flow cytometry. Serum soluble OX40L (sOX40L) and C-reactive protein levels were measured by commercially available enzyme-linked immunosorbent assay kit.
The expression of OX40 and OX40L in peripheral CD4 T lymphocytes in patients with UA [26.7 +/- 3.4 and 45.5 +/- 8.1 mean fluorescence intensity (MFI)] and AMI (27.4 +/- 4.6 and 55.7 +/- 9.4 MFI) were significantly higher than those in patients with SA (6.5 +/- 1.4 and 12.4 +/- 3.2 MFI) and controls (7.3 +/- 1.5 and 11.9 +/- 6.1 MFI). sOX40L in patients with UA (38.7 +/- 6.9 ng/mL) and AMI (39.5 +/- 7.3 ng/mL) were significantly higher than those in patients with SA (8.4 +/- 1.4 ng/mL) (P < 0.01) and controls (8.9 +/- 2.3 ng/mL) (P < 0.01). C-reactive protein level in serum in patients with UA (14.6 +/- 3.3 ng/mL) and AMI (15.0 +/- 4.3 ng/mL) were also higher than those in patients with SA (1.4 +/- 0.4 ng/mL) and controls (1.3 +/- 0.3 ng/mL). It was interesting that there was a peak level of sOX40L at 12 hours after AMI in patients with AMI. A positive correlation was found between sOX40L and serum C-reactive protein levels (r = 0.71; P < 0.0001).
Patients with acute coronary syndromes showed increased coexpression of OX40 system, which may create a proinflammatory and prothrombotic milieu for aggravating the development of atherosclerosis and instability of atherosclerotic plaques, and sOX40L is a potential marker for predicting the severity of coronary heart diseases.
探讨 OX40-OX40 配体（OX40L）系统的上调是否与冠心病患者冠状动脉粥样硬化斑块的稳定性有关。
纳入 30 例正常对照者和 250 例患者，包括 80 例稳定性心绞痛（SA）患者、110 例不稳定型心绞痛（UA）患者和 60 例急性心肌梗死（AMI）患者。采用流式细胞术分析外周血 CD4 T 淋巴细胞中 OX40 和 OX40L 的表达。采用商用酶联免疫吸附试验试剂盒测定血清可溶性 OX40L（sOX40L）和 C 反应蛋白水平。
UA [26.7±3.4 和 45.5±8.1 平均荧光强度（MFI）]和 AMI [27.4±4.6 和 55.7±9.4 MFI]患者外周血 CD4 T 淋巴细胞中 OX40 和 OX40L 的表达明显高于 SA [6.5±1.4 和 12.4±3.2 MFI]和对照组 [7.3±1.5 和 11.9±6.1 MFI]（P<0.01）。UA 患者的 sOX40L [38.7±6.9 ng/mL]和 AMI 患者的 sOX40L [39.5±7.3 ng/mL]均明显高于 SA 患者 [8.4±1.4 ng/mL]（P<0.01）和对照组 [8.9±2.3 ng/mL]（P<0.01）。UA 患者 [14.6±3.3 ng/mL]和 AMI 患者 [15.0±4.3 ng/mL]血清中的 C 反应蛋白水平也高于 SA 患者 [1.4±0.4 ng/mL]和对照组 [1.3±0.3 ng/mL]（P<0.01）。有趣的是，AMI 患者在 AMI 后 12 小时 sOX40L 水平达到峰值。sOX40L 与血清 C 反应蛋白水平呈正相关（r=0.71；P<0.0001）。
急性冠状动脉综合征患者 OX40 系统共表达增加，可能为加重动脉粥样硬化发展和粥样硬化斑块不稳定创造促炎和促血栓形成环境，sOX40L 是预测冠心病严重程度的潜在标志物。
